基本信息
views: 1
Career Trajectory
Bio
My laboratory is focused on understanding the molecular mechanisms and cellular interactions that promote immune suppression and failure to control cancer and chronic infections. Our goal is then to use this information to design therapies that block these suppressive pathways to broadly restore immunity to eliminate these diseases. It is becoming increasingly evident that host-based immunosuppressive factors induced during cancer and chronic virus infections inhibit T cells from curing the disease. Importantly many of the same factors suppress the immune responses against multiple chronic diseases, suggesting conserved underlying mechanisms of immune dysfunction; and as a result, that it will be possible to simultaneously develop immunotherapies that target central drivers of immunosuppression to fight both chronic viruses and tumors.
In particular, we were the first to discover many new mechanisms of immune regulation during chronic infection and many of our discoveries are being tested in pre-clinical and clinical studies to treat human disease. In addition to immunosuppression, cancer and chronic infections are associated with inflammation that is increasingly being recognized to further exacerbate immune exhaustion and promote disease progression. Although these two seemingly opposing programs of inflammation and immunosuppression co-exist and each associated with worsened disease, their relationship is unclear. Our group recently discovered that in addition to their critical antiviral and immunostimulatory roles, type I interferons (IFN-I) are core regulators of the diverse suppressive pathways that suppress immunity during viral persistence and demonstrated that IFN-I signaling could be blocked to restore immune health and control chronic virus infection. We are currently extending these studies to cancer and cancer immunotherapy to understand how chronic IFN alters anti-tumor immunity and the potential use of distinct IFN signatures as biomarkers of therapeutic efficacy.
In order to understand the immune mechanisms that promote control of cancer and chronic infections, our laboratory uses multiple cutting-edge high dimensional approaches to interrogate mouse tumor models, human tissues and clinical trials. Among the interests in the laboratory are to explore: (1) the mechanisms of immunosuppression that drive innate cell dysfunction and T cell exhaustion in cancer and chronic virus infections and how to therapeutically overcome them to cure these diseases; (2) how chronic inflammation and type I interferon signaling alter immunity to both propel and inhibit antiviral and anti-tumor immunity; (3) to uncover the mechanisms of CD4 T cell help that enable and sustain immune control to chronic diseases, and the dysfunctions that prevent them; and (4) to understand the relationship between the tissue microenvironment and immune regulation in potentiating disease progression or control. Overall, our goal is to use this information to develop novel and comprehensive immunotherapeutic strategies to fight chronic viruses and cancers.
In particular, we were the first to discover many new mechanisms of immune regulation during chronic infection and many of our discoveries are being tested in pre-clinical and clinical studies to treat human disease. In addition to immunosuppression, cancer and chronic infections are associated with inflammation that is increasingly being recognized to further exacerbate immune exhaustion and promote disease progression. Although these two seemingly opposing programs of inflammation and immunosuppression co-exist and each associated with worsened disease, their relationship is unclear. Our group recently discovered that in addition to their critical antiviral and immunostimulatory roles, type I interferons (IFN-I) are core regulators of the diverse suppressive pathways that suppress immunity during viral persistence and demonstrated that IFN-I signaling could be blocked to restore immune health and control chronic virus infection. We are currently extending these studies to cancer and cancer immunotherapy to understand how chronic IFN alters anti-tumor immunity and the potential use of distinct IFN signatures as biomarkers of therapeutic efficacy.
In order to understand the immune mechanisms that promote control of cancer and chronic infections, our laboratory uses multiple cutting-edge high dimensional approaches to interrogate mouse tumor models, human tissues and clinical trials. Among the interests in the laboratory are to explore: (1) the mechanisms of immunosuppression that drive innate cell dysfunction and T cell exhaustion in cancer and chronic virus infections and how to therapeutically overcome them to cure these diseases; (2) how chronic inflammation and type I interferon signaling alter immunity to both propel and inhibit antiviral and anti-tumor immunity; (3) to uncover the mechanisms of CD4 T cell help that enable and sustain immune control to chronic diseases, and the dysfunctions that prevent them; and (4) to understand the relationship between the tissue microenvironment and immune regulation in potentiating disease progression or control. Overall, our goal is to use this information to develop novel and comprehensive immunotherapeutic strategies to fight chronic viruses and cancers.
Research Interests
Papers共 127 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Trends in Immunologyno. 4 (2024): 303-313
STAR Protocolsno. 2 (2024): 103064-103064
Sara Lamorte,Luke Neufeld,Rene Quevedo, Xin Zhang,M. Teresa Ciudad,Robbie Jin, Zaid Kamil Saeed,Mikael C. I. Karlsson,Tak W. Mak,David Munn,David Brooks,Tracy McGaha
Journal of Immunologyno. 1 (2023): 84.12-84.12
JOURNAL OF RHEUMATOLOGYno. 7 (2023): 22-22
Cited0Views0Bibtex
0
0
Cell reportsno. 9 (2023): 113047-113047
Hepatology communicationsno. 12 (2023)
bioRxiv : the preprint server for biology (2023)
Molecular biology of the cellno. 9 (2023)
Marc de Perrot,Amin Zia,Licun Wu,Giselle Boukhaled, Ramy Gadalla,Ben Wang,David Brooks, Jeffrey Man,Trevor Pugh,Prodipto Pal, Fatemeh Zaeimi, Hebe Chu,
CANCER IMMUNOLOGY RESEARCHno. 12 (2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn